Drug Trial Radar · NCT05553301
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older
Last checked: Nov 20, 2026Latest source record: Jan 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
560
Actual
Start
Oct 3, 2022
Primary completion
Jan 19, 2024
Study completion Jan 19, 2024
Sponsor
- Lead sponsor
- Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Sep 23, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular (IM) injection of up to 2 dose levels of Quadrivalent Influenza messenger ribonucleic acid (mRNA) Vaccine MRT5407 compared to an active control (QIV standard-dose (SD), QIV high-dose (HD) \[adults ≥ 65 years of age only\], or quadrivalent recombinant influenza vaccine (RIV4)) in adults 18 years of age and older.
Conditions
- Influenza Immunization
Interventions
Quadrivalent Influenza mRNA Vaccine MRT5407Biological
Pharmaceutical Form: Liquid frozen solution in a vial Route of Administration: Intramuscular Injection
Quadrivalent Recombinant Influenza VaccineBiological
Pharmaceutical Form: Liquid frozen solution in a vial Route of Administration: Intramuscular Injection
Quadrivalent Influenza Standard Dose VaccineBiological
Pharmaceutical Form: Liquid suspension for injection in pre-filled syringe Route of Administration: Intramuscular Injection
Quadrivalent Influenza High-Dose VaccineBiological
Pharmaceutical Form: Liquid suspension for injection in pre-filled syringe Route of Administration: Intramuscular Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with immediate adverse events (AEs)Time frame: Within 30 minutes after injection
- Number of participants with solicited injection site and systemic reactionsTime frame: Up to 7 days after injection
- Number of participants with unsolicited AEsTime frame: Up to 28 days after injection
- Number of participants with medically attended adverse events (MAAE)sTime frame: Up to 28 days after injection
- Number of participants with serious adverse events (SAEs)Time frame: From Day one to Day 366
- Number of participants with out-of-range biological test resultsTime frame: Up to 8 days after injection
- Individual Hemagglutination inhibition (HAI) titerTime frame: At Day 1 and Day 29
- Percentage of participants with detectable antibody HAI titers greater than or equal to (≥) 10 [1/dil]Time frame: At Day 1 and Day 29
- Individual HAI titer ratioTime frame: At Day 1 and Day 29
- Number of participants archiving HAI seroconversion against AntigensTime frame: At Day 1 and Day 29
- Percentage of participants with antibody HAI titers greater than or equal to (≥) 40 [1/dil]Time frame: At Day 29
- Percentage of participants with 2-fold and 4-fold rise in HAI titersTime frame: At Day 1 and Day 29
Locations
25 sites in 2 countries. Site status is shown where the registry gives one.
Peninsula Research Associates Site Number : 8400025
Rolling Hills Estates, California
Optimal Research Site Number : 8400059
San Diego, California
California Research Foundation Site Number : 8400008
San Diego, California
Accel Clinical Research-Deland Clinical Research Unit Site Number : 8400052
DeLand, Florida
SIMEDHealth, LLC Site Number : 8400024
Gainesville, Florida
Indago Research and Health Center Site Number : 8400014
Hialeah, Florida
Cenexel Research Centers of America Site Number : 8400048
Hollywood, Florida
Dade Research Center Site Number : 8400011
Miami, Florida
Suncoast Research Group, LLC Site Number : 8400038
Miami, Florida
Florida International Research Center Site Number : 8400051
Miami, Florida
Palm Beach Research Center Site Number : 8400020
West Palm Beach, Florida
DM Clinical Research Site Number : 8400032
Melrose Park, Illinois
DM Clinical Research - Chicago Site Number : 8400028
River Forest, Illinois
Brengle Family Medicine Site Number : 8400005
Indianapolis, Indiana
AMR Lexington Site Number : 8400054
Lexington, Kentucky
AMR Kansas City Site Number : 8400006
Kansas City, Missouri
Velocity Clinical Research Site Number : 8400003
Omaha, Nebraska
Coastal Carolina Research Center - N Charleston Site Number : 8400010
North Charleston, South Carolina
AMR Knoxville Site Number : 8400046
Knoxville, Tennessee
Elligo Health Research Site Number : 8400056
Austin, Texas
Sun Research Institute Site Number : 8400030
San Antonio, Texas
Clinical Trials of Texas, Inc. Site Number : 8400026
San Antonio, Texas
DM Clinical Research - Sugar Land Site Number : 8400031
Sugar Land, Texas
Investigational Site Number : 6300003
Barrio Sabana, Puerto Rico
Investigational Site Number : 6300002
San Juan, Puerto Rico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.